Company news
Arrowhead Pharmaceuticals, Inc. news in 2023
Arrowhead Pharmaceuticals, Inc.'s news releases, calls and decks from 2023, newest first.
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease
December 20, 2023
Arrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 19, 2023
Arrowhead Pharmaceuticals Reports Fiscal 2023 Year End Results
November 28, 2023
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy
November 27, 2023
Arrowhead Pharmaceuticals to Participate in Piper Sandler 35th Annual Healthcare Conference
November 20, 2023
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Year End Results
November 15, 2023
Arrowhead Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023
November 12, 2023
Arrowhead Pharmaceuticals to Participate in Jefferies London Healthcare Conference
November 5, 2023
Arrowhead Pharmaceuticals to Present New Phase 2 Clinical Data on Cardiometabolic Pipeline at AHA 2023
November 1, 2023
Arrowhead Pharmaceuticals to Participate in Upcoming October 2023 Conferences
October 2, 2023
Arrowhead Presents Data on Pulmonary Pipeline at ERS 2023
September 10, 2023
Arrowhead Pharmaceuticals to Participate in Upcoming September 2023 Conferences
August 31, 2023
Arrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results
August 6, 2023
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Third Quarter Results
July 23, 2023
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1/2 Study of ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy
July 16, 2023
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1
June 26, 2023
Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease
June 23, 2023
Arrowhead Pharmaceuticals to Participate in Upcoming June 2023 Conferences
June 5, 2023
Arrowhead Hosts R&D Day Highlighting Its Pipeline of RNAi Therapeutics
May 31, 2023
Arrowhead Presents Interim Data from ARO-ANG3 Phase 2 GATEWAY Study in Patients with HoFH
May 22, 2023
Arrowhead Pharmaceuticals Completes Enrollment of Phase 3 PALISADE Clinical Trial Evaluating ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome
May 15, 2023
Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
May 14, 2023
Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results
May 1, 2023
Arrowhead Pharmaceuticals’ Proprietary Pulmonary TRiM™ Platform Achieves High Levels of Target Gene Knockdown and Long Duration of Effect
April 24, 2023
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Second Quarter Results
April 17, 2023
Arrowhead Pharmaceuticals to Host R&D Day on Pipeline of RNAi Therapeutics
April 11, 2023
First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead
April 3, 2023
Arrowhead Pharmaceuticals Announces $30 Million Milestone Payment from GSK
April 2, 2023
Arrowhead Receives FDA Fast Track Designation for ARO-APOC3
March 19, 2023
Arrowhead Pharmaceuticals to Present at 43rd Annual Cowen Health Care Conference
March 2, 2023
Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
February 27, 2023
Arrowhead Pharmaceuticals Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results
February 14, 2023
Arrowhead Pharmaceuticals Reports Fiscal 2023 First Quarter Results
February 5, 2023
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis
February 1, 2023
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 First Quarter Results
January 24, 2023
Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
January 8, 2023
Calls in 2023
Decks in 2023
- American Heart Association Scientific Sessions 2023
Conference · 14 slides · 2023